Finanical Statements
Egyptian International Pharmaceuticals (EIPICO) (PHAR.CA) Reports Its Financial Results (Consolidated) for The Period From 01/01/2026 to 31/03/2026
Published at 17 May 2026 at 10:45Egyptian International Pharmaceuticals (EIPICO)Related stock:Egyptian International Pharmaceuticals (EIPICO) stockAll Egyptian International Pharmaceuticals (EIPICO) disclosures
Disclosure summary
Company Name: Egyptian International Pharmaceuticals (EIPICO)
ISIN Code: EGS38081C013
Currency: Egyptian Pound
F/S (Consolidated) Period: From 01/01/2026 to 31/03/2026
Net profit: 284,419,447
F/S (Consolidated) Period: From 01/01/2025 to 31/03/2025
Net Comparative profit: 318,741,936
Audit Status: Reviewed
Source: Egyptian International Pharmaceuticals (EIPICO)
Taking minority rights into consideration
The BoD Report in Arabic (290 KB)
The Consolidated Financial Statements in English (4,036 KB)
The Consolidated Financial Statements in Arabic (971 KB)
The BoD Report in English (137 KB)
ISIN Code: EGS38081C013
Currency: Egyptian Pound
F/S (Consolidated) Period: From 01/01/2026 to 31/03/2026
Net profit: 284,419,447
F/S (Consolidated) Period: From 01/01/2025 to 31/03/2025
Net Comparative profit: 318,741,936
Audit Status: Reviewed
Source: Egyptian International Pharmaceuticals (EIPICO)
Taking minority rights into consideration
The BoD Report in Arabic (290 KB)
The Consolidated Financial Statements in English (4,036 KB)
The Consolidated Financial Statements in Arabic (971 KB)
The BoD Report in English (137 KB)